TABLE OF CONTENTS

Foreword

Introduction

1.0 Medical Roles and Responsibilities
   1.1 Indications for Consultation with Transfusion Medicine Medical Staff Qualifications
   Table 1.1: Indications for Immediate Consultation
   Table 1.2: Transfusion Emergency and TM Medical Director or Delegate is not responding

2.0 Quality System Management
   2.1 Components of Assessment Quality System Essentials

3.0 Informed Consent and Refusal of Consent

4.0 Daily Operations
   4.1 Patient Identification and Sample Labeling Criteria
   4.2 Pre-transfusion Examinations
   Table 4.1: Clinical Significance of Antibodies and Provision of Red Blood Cells
   4.3 Inventory Management

5.0 Appropriate Use of Blood Components for Adults
   5.1 Transfusion of Red Blood Cells to Adults
   Table 5.1: Transfusion Guidelines for Red Blood Cells
   Table 5.2: Transfusion of Red Blood Cells to Adults
   Table 5.3: Selection ABO Compatible Donor Red Blood Cells
   5.2 Transfusion of Platelets to Adults
   Table 5.4: Guidelines for Platelet Transfusion in Adults
   Table 5.5: Relative Contraindications to Adult Platelet Transfusion
   5.3 Transfusion of Frozen Plasma to Adults
   5.4 Transfusion of Cryosupernatant Plasma to Adults
   5.5 Transfusion of Cryoprecipitate to Adults
   5.6 Use of Prothrombin Complex Concentrates (PCCs)

6.0 Special Product Selection
   6.1 Platelet Selection
   6.2 Clinical Practice Recommendations for the Use of Non-ABO Specific Platelets
   6.3 Special Circumstances
   6.4 Platelet Refractoriness and Indications for HLA matched platelets
   6.5 Clinical Practice Recommendations for Management of Platelet Refractoriness
   6.6 CMV Seronegative Red Blood Cells and Platelets
   6.7 Indications for use of CMV seronegative red blood cells and platelets
   6.8 Irradiated Blood Components
   Table 6.1: Recommended Indications for the Use of Irradiated Components
   6.9 Washed Red Blood Cells and Platelets
   6.10 Indications for Washed Red Blood Cells
   6.11 Indications for Washed or Plasma Depleted Platelets
   6.12 Emergency Release of Red Blood Cell Units
7.0 Appropriate Use of Manufactured Blood Products
   7.1 Appropriate Use of Plasma Fractionated Products
   7.2 Indications for the Use of Albumin
   7.3 Indications for the Use of Intravenous Immunoglobulin (IVIG)
   Table 7.1: Use of Recombinant* and Plasma Derived Products that Do Not Require a Special Access Program (SAP) Approval
   Table 7.2: Use of Products that Require Approval through Health Canada Special Access Program or SAP
   7.4 Use of Recombinant Factor VIIa, Erythropoietin

8.0 Appropriate Use of Blood Components in Neonates and Pediatric Patients
   8.1 Neonatal Red Blood Cell and Platelet Transfusion
   8.2 Neonatal Patient Management
   Table 8.1: Threshold and Target Hemoglobin Levels for Neonatal Red Blood Cell Transfusion
   Table 8.2: Indications for Neonatal Platelet Transfusion
   8.3 Pediatric Blood Component Transfusion
   Table 8.3: Pediatric Red Blood Cell Transfusion Guidelines
   8.4 Transfusion of Frozen Plasma to Pediatric Patients
   8.5 Transfusion of Platelets to Pediatric Patients more than 4 months of age
   Table 8.4: Indications for Pediatric Platelet Transfusion (other than neonate)
   8.6 Management of Congenital Anemias
   8.7 Management of Transfusion in Pediatric Patients with Autoimmune Hemolytic Anemia

9.0 Special Transfusion Situations
   9.1 Support of a Patient with a Signed Refusal of Consent for Transfusion
   9.2 Management of a Patient Requiring Massive Transfusion
   9.3 Switching ABO Group in Massive Transfusion or During Inventory Shortage
   Table 9.1: Selection Order of ABO Compatible Donor Red Blood Cells
   Table 9.2: Selection Order of ABO Group for Platelets or Plasma
   9.4 Switching from RhD Negative to RhD Positive Red Blood Cells in Massive Transfusion
   9.5 Massive Transfusion in a Patient with Alloantibodies
   9.6 Transfusion Management of Autoimmune Hemolytic Anemia (AIHA)
   9.7 Transfusion Support for Patients Following Solid Organ or Allogeneic Bone Marrow or Stem Cell Transplant
   9.8 Transfusion Support of Patients with Sickle Cell Syndromes

10.0 Disaster and Contingency Plans

11.0 Transfusion Reactions
   Table 11.1: Ontario TTISS Transfusion Reaction Chart
   Table 11.2: Algorithm for management of transfusion-associated fever
   11.1 Urticaria and other allergic reactions
   Table 11.3: Management Algorithm for Allergic Reactions
   11.2 Dyspnea
   Table 11.4: Management Algorithm for Dyspnea
   11.3 Transfusion-associated circulatory overload (TACO)
   11.4 Hypotension (bradykinin mediated)
   Table 11.5: Management Algorithm for Hypotension
   11.5 Cytopenias after transfusion
   11.6 Transfusion-associated graft-versus-host disease (GvHD)
   11.7 Rare causes of transfusion-associated cytopenia
   11.8 Hemolysis after transfusion
   11.9 Adverse reactions to intravenous immunoglobulin (IVIG)
   Table 11.6: Adverse Reactions to IVIG